País: Estats Units
Idioma: anglès
Font: NLM (National Library of Medicine)
CAPGUARD™ Tablets contain 11.4 or 57.0 mg of nitenpyram, which belongs to thechemical class of neonicotinoids. Nitenpyram kills adult fleas.
Sergeant's Pet Care Products Inc.
OTC
New Animal Drug Application
SENTRY CAPGUARD- NITENPYRAM TABLET SERGEANT'S PET CARE PRODUCTS INC. ---------- SENTRY CAPGUARD SENTRY CAPGUARD (nitenpyram) CAPGUARD™ is an oral tablet for dogs, puppies, cats and kittens 2 POUNDS OF BODY WEIGHT OR GREATER AND 4 WEEKS OF AGE AND OLDER. ACTIVE INGREDIENTS CAPGUARD™ Tablets contain 11.4 or 57.0 mg of nitenpyram, which belongs to the chemical class of neonicotinoids. Nitenpyram kills adult fleas. WARNINGS Not for human use. Keep this and all drugs out of the reach of children. DIRECTIONS CAPGUARD™ Tablets kill adult fleas and are indicated for the treatment of flea infestations on dogs, puppies, cats and kittens 2 POUNDS OF BODY WEIGHT OR GREATER AND 4 WEEKS OF AGE AND OLDER. A single dose of CAPGUARD™ should kill the adult fleas on your pet. If your pet gets re-infested with fleas, you can safely give another dose as often as once per day. To give CAPGUARD™ Tablets, place the pill directly in your pet’s mouth or hide it in food. If you hide the pill in food, watch closely to make sure your pet swallows the pill. If you are not sure that your pet swallowed the pill, it is safe to give a second pill. Treat all infested pets in the household. Fleas can reproduce on untreated pets and allow infestations to persist. DOS AGE CAPGUARD™ Tablets should be administered according to the following schedule. WEIGH YOUR PET PRIOR TO ADMINISTRATION TO ENSURE PROPER DOSAGE. DO NOT ADMINISTER TO PETS UNDER 2 POUNDS. RECOMMENDED DOSAGE SCHEDULE SPECIES BODY WEIGHT DOSE NITENPYRAM PER TABLET Dog or Cat 2-25 lbs. One tablet 11.4 mg Dog 25.1-125 lbs. One tablet 57.0 mg ADVERSE REACTIONS Pre-approval laboratory and clinical studies showed that CAPGUARD™ Tablets are safe for use in dogs and cats, puppies and kittens 2 POUNDS OF BODY WEIGHT OR GREATER AND 4 WEEKS OF AGE AND OLDER. (SEE POST-APPROVAL EXPERIENCE SECTION). ® ™ POST-APPROVAL EXPERIENCE (REV. 2011): The following adverse events are based on post-approval adverse drug experience reporting. Not all adverse reactions are reported to FDA CVM. I Llegiu el document complet